Statins: lower lipids and better bones?

Abstract

Although statins are widely used as cholesterol-lowering drugs, a recent study suggests that these compounds have anabolic effects on bone and could be developed into new treatments for common metabolic bone diseases such as osteoporosis

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Effects of mevalonate pathway inhibition on bone metabolism.

References

  1. 1

    Mundy, G. et al. Stimulation of bone formation in vitro and in rodents by statins. Science 286, 1946– 1949 (1999).

  2. 2

    Alberts, A.W. et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. USA 77, 3957–3961 ( 1980).

  3. 3

    Hamelin, B.A. & Turgeon, J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors . Trends Pharmacol. Sci. 19, 26– 37 (1998).

  4. 4

    Zhang, F.L. & Casey, P.J. Protein prenylation: molecular mechanisms and functional consequences. Ann. Rev. Biochem. 65, 241–269 (1996).

  5. 5

    Garrett, I.R., Escobedo, A. & Mundy, G.R. N2-containing bisphosphonates risedronate and ibandronate stimulate bone formation in organ culture. J. Bone Miner. Res. 14 S525 (abstract) (1999).

  6. 6

    Luckman, S.P. et al. J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13, 58 –589 (1998).

  7. 7

    Fisher, J.E. et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc. Natl. Acad. Sci. USA 96, 133–138 ( 1999).

  8. 8

    van Beek, E. et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 264, 108–111 ( 1999).

  9. 9

    Plotkin, L.I. et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J. Clin. Invest. 104, 1363 –1374 (1999).

  10. 10

    Bauer, D.C. et al. Statin use, bone mass and fracture: an analysis of two prospective studies. J. Bone Miner. Res. 14, S179 (abstract) (1999).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rogers, M. Statins: lower lipids and better bones?. Nat Med 6, 21–23 (2000). https://doi.org/10.1038/71484

Download citation

Further reading